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Short title: IL-36 overexpression in Acute Generalized Exanthematous Pustulosis 
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ABSTRACT 
 
Acute generalized exanthematous pustulosis (AGEP) is a severe adverse cutaneous drug 
reaction. Although an involvement of drug-specific T cells has been reported, the 
physiopathology of AGEP and mechanism of neutrophilic skin inflammation remains 
incompletely understood. Recently, mutations in IL-36RN, the gene encoding the IL-36 
receptor antagonist, have been reported to be more frequent in AGEP patients and pustular 
psoriasis. Here, we show that IL-36 cytokines, in particular IL-36γ, is highly expressed in 
lesional skin of AGEP patients, keratinocytes and macrophages being a major source of IL-
36γ. Such an IL-36γ overexpression could not be observed in patients with drug-induced 
maculo-papular rash (MPR). In vitro, the causative drug specifically induced IL-36γ release 
either directly by peripheral blood monocytes from AGEP patients, or indirectly by 
keratinocytes in presence of autologous peripheral blood mononuclear cells. Such culprit drug 
induction of IL-36γ secretion in vitro was specific for AGEP and involved the sensing of 
drug/albumin complex as danger signal by Toll-like receptor 4. Our results suggest that IL-
36γ secretion by monocytes/macrophages and keratinocytes in response to culprit drug 
exposure likely plays a key role in the pathogenesis of AGEP.  
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INTRODUCTION 
 
Acute generalized exanthematous pustulosis (AGEP) is a severe cutaneous adverse drug 
reaction (ADR) caused mainly by antibiotics, antimalarials and antifungals (Sidoroff et al., 
2001). Clinically, AGEP is characterized by a disseminated eruption of sterile nonfollicular 
pustules on the background of a widespread erythematous skin eruption, accompanied with 
fever and peripheral blood neutrophilia. To date, the pathophysiology of AGEP remains not 
fully elucidated. However, AGEP is currently considered as a T cell-mediated disease 
(Pichler, 2003) and is currently seen a delayed type hypersensitivity reaction.  Indeed, drug-
specific T cells are suspected to play a central role in AGEP as evidenced by the high levels 
of T cell stimulation induced by causative (culprit) drugs as measured by the lymphocyte 
transformation test (LTT) (Anliker and Wuthrich, 2003). Furthermore, drug-specific CD4+ 
and CD8+ T cells have been derived in vitro from AGEP patients’ peripheral blood. Most of 
these drug-specific T cells (Nishio et al., 2007) produce IL-8 (Britschgi and Pichler, 2002, 
Britschgi et al., 2001), a powerful neutrophil chemoattractant. IL-8-producing T cells are 
therefore, considered to be the cause of neutrophil survival and recruitment to the skin during 
the course of the disease (Schaerli et al., 2004). It has also been suggested that Th17 effector 
cytokines, namely IL-17 and IL-22, stimulate keratinocytes to produce IL-8, and that 
keratinocyte-derived IL-8 also contributes to neutrophil accumulation in AGEP patients’ skin 
(Kabashima et al., 2011).  Hence, T cell- and keratinocyte-derived IL-8 has been proposed to 
be responsible for the recruitment of neutrophils to the intraepithelial pustules. 
AGEP shares certain clinical and histological features with pustular psoriasis. Recently, 
genetic studies identified mutations in the IL-36 receptor antagonist gene (IL-36RN) in 
patients with general pustular psoriasis (Kanazawa et al., 2013, Marrakchi et al., 2011, 
Onoufriadis et al., 2011, Sugiura et al., 2012). Interestingly, mutations in IL-36RN have also 
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been reported in AGEP (Navarini et al., 2013), suggesting that IL-36 signaling dysregulation 
is involved in the physiopathology of both pustular diseases. IL-36 receptor antagonist (IL-
36Ra) inhibits the binding of IL-36α, β and γ to their receptor. A mutation in IL-36RN may 
therefore result in exacerbated IL-36 signaling leading to the production of IL-1, IL-6 and IL-
8 and subsequent neutrophilic skin infiltration with pustule formation. 
IL-36 cytokines have emerged as important cytokines mediating inflammatory responses in 
the skin. Indeed, several reports have shown that all IL-36 isoforms are overexpressed in 
psoriatic skin (Debets et al., 2001, Gresnigt and van de Veerdonk, 2013, He et al., 2013, 
Johnston et al., 2011). In keratinocytes, production of IL-36 family members can be induced 
by TNF, IL-17 and IL-22, cytokines known to be involved in psoriasis which further supports 
an important role for IL-36 in this disease (Carrier et al., 2011). Recently, it has been reported 
that antigen-presenting cells located in human skin, express high levels of IL-36R and are 
responsive to IL-36 cytokines (Dietrich et al., 2016), an observation that further supports an 
important role of IL-36 in skin biology.  
Here, we provide evidence that drugs causing AGEP can specifically trigger IL-36 cytokine 
production by peripheral blood monocytes via Toll-like receptor 4 and by keratinocytes from 
AGEP patients and subsequently induce IL-8 by peripheral blood mononuclear cells in an IL-
36-dependent manner. These observations are supportive of a drug-specific dysregulation of 
IL-36 signaling as a possible driver of AGEP pathogenesis, and identify myeloid cells and 
keratinocytes as important players in AGEP.  
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RESULTS 
 
Enhanced IL-36 expression in lesional skin of AGEP patients 
First, we performed gene expression profiling (GEO Accession number GSE121421) using 
Affymetrix Human Exon 1.0 ST chips (see supplementary material for description). Total 
RNA were extracted from lesional skin from patients with AGEP (n=8) or maculo-papular 
rash (MPR, n=6), and from skin from healthy individuals (n=7). The hierarchical clustering of 
genes differentially expressed in AGEP, MPR and healthy skin revealed a perfect segregation 
of these three conditions based on the gene expression profile of individual samples and the 
magnitude of change in gene expression (Fig.1a and Table S1). Interestingly, the IL-36γ gene 
(IL1F9) was found to be overexpressed in AGEP skin when compared to healthy skin 
(ratio=3.06, p=0.0006; Table S2) and MPR (ratio=2.54, p=0.005; Table S3). Using 
quantitative PCR, we then analyzed the expression of IL-36 in skin biopsies from AGEP 
(n=16) and maculo-papular rash (MPR), a milder form of cutaneous reaction to drugs (n=16). 
The expression of IL-36α, β and γ was found to be upregulated in AGEP skin when compared 
to MPR (IL-36α 15-fold, p<0.001; IL-36β 28-fold, p<0.001; IL-36γ 32-fold, p<0.001) and 
normal skin (IL-36α 7-fold, p<0.001; IL-36β 1.35-fold, p<0.05; IL-36γ 3-fold, p<0.001) (Fig. 
1b). The expression of IL-36RN was found to be higher (4.5-fold, p<0.001) in AGEP skin as 
compared to MPR whereas it was not different to that found in normal skin. IL-36R was 
similarly expressed in both diseases.  
The relative expression of IL-36β was however low as compared to IL-36α and γ. Therefore, 
we further analyzed the expression and tissue distribution of IL-36α and γ by labeling AGEP 
and MPR lesional skin biopsies with antibodies to both cytokines. IL-36α and γ were found to 
be highly expressed in pustular and peri-pustular regions of AGEP skin (Fig.1c). Both 
keratinocytes and dermal immune cells infiltrating pustular areas were found to produce IL-
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36α and γ. In contrast, IL-36γ was weakly expressed in MPR skin biopsies and IL-36α was 
barely detectable. In AGEP lesional skin, IL-36γ was predominantly expressed by 
keratinocytes in the epidermis and by immune cells infiltrating the dermis in pustular areas. 
Also, IL-36γ staining was particularly intense in non-pustular epidermis surrounding the 
pustules in AGEP. As previously reported (Song et al., 2016), IL-36α was also expressed in 
pustules from patients suffering from pustular psoriasis (PP) and, like in AGEP biopsies, IL-
36γ was the predominant form in the epidermis (Fig. 1c). Neither IL-36α, nor IL-36γ could be 
detected in skin specimens from healthy donors (Fig. S1). 
 
IL-36 production by keratinocytes and macrophages in lesional skin of AGEP patients 
To identify which cell types release IL-36α and γ in AGEP skin, we co-labeled AGEP biopsy 
sections with antibodies to IL-36α and γ and antibodies to CD68 to identify macrophages, and 
to CD3 to identify T-cells (Fig. 2). IL-36α was predominantly expressed by CD68+ 
macrophages (41.17%±4.71 of positively labeled cells) and to a lesser extent by keratinocytes 
and CD3+ T cells (27.33%±2.17 and 22.33%±2.39 of positively labeled cells, respectively). 
IL-36γ was predominantly expressed by keratinocytes and CD68+ macrophages 
(44.08%±4.47 and 43.17%±3.31 of positively labeled cells, respectively) and to a lesser 
extent by CD3+ T cells (15.17%±1.26 of positively labeled cells). In contrast, IL-36α and IL-
36γ were not expressed by neutrophils present in pustular areas (Fig. S2). 
 
Rapid culprit drug-specific induction of IL-36γ in monocytes in AGEP  
Immunofluorescence analyses of AGEP biopsies suggested that, in addition to keratinocytes, 
immune cells may also represent an important source of IL-36γ in the skin. Therefore, we 
assessed whether peripheral blood mononuclear cells (PBMC) taken from AGEP patients 8, 9 
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and 20 more than 6 months after the ADR - when in complete remission - were still able to 
respond directly to the causative drug. To this end, PBMC from patients having experienced 
AGEP were exposed to their respective causative drug or an irrelevant control drug – that did 
not cause AGEP in the tested patients - in ELISPOT plates. The number of IL-36γ+ spots was 
counted after 1, 2, 4, 6 and 8 hrs. IL-36γ release was detected in PBMC from AGEP patients 
already after 1 hr of exposure to their respective culprit drug (1.7-fold more spots than control 
drug, p<0.001) and reached a plateau after 4 hrs (2.7-fold more spots than control drug, 
p<0.001) (Fig. 3a, left panel), whereas no increase in IL-36γ production was observed with 
control drugs that did not cause AGEP in the tested patients (Fig. 3a, right panel and Fig. S3). 
In contrast, none of the culprit drugs involved in AGEP did induce IL-36γ secretion in PBMC 
from MPR patients with proven sensitization to the same drug. Similarly, none of the drugs 
used was able to induce IL-36γ secretion in PBMC from healthy blood donors. Of note, IL-
36γ production was concentration dependent and was exclusively observed in PBMC from 
patients exposed to the drug having caused AGEP (Fig. S3) whereas none of the drugs used in 
this study was able to induce IL-36γ in drug-sensitized MPR patients’ or healthy donors’ 
PBMCs even at the highest concentration. 
Since immunofluorescence analyses of AGEP skin lesions revealed that macrophages and, to 
a lesser extent, T cells are possible sources of IL-36, we sorted CD14+ (monocytes) and CD3+ 
cells (T cells) from patients’ PBMC and exposed them to culprit or control drug to evaluate 
IL-36γ secretion by ELISPOT (Fig. 3b). Whereas the control drug did not induce IL-
36γ secretion in PBMC or in CD14+ and CD3+ cells, the culprit drug was able to induce IL-
36γ secretion in CD14+ cells at levels similar to those observed with total PBMC. In contrast, 
the culprit drug was not able to induce IL-36γ secretion in CD3+ PBMC. These results suggest 
that PBMC from patients having experienced AGEP are able to respond directly and 
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specifically to the causative drug and that monocytes/macrophages are an important source of 
IL-36 production in response to culprit drug exposure. 
 
IL-36 induction by culprit drugs in keratinocytes and PBMC from patients having 
experienced AGEP 
By immunolabeling, both keratinocytes and macrophages were positively labeled for IL-36α 
and γ in pustular areas of AGEP biopsies (Fig. 2). To assess a possible cross-talk between 
macrophages and keratinocytes, and the relative contribution of each cell type to drug-induced 
IL-36 secretion, we performed co-culture experiments using autologous hair follicle-derived 
keratinocytes and PBMC from three patients having experienced AGEP but in remission at 
the time of blood and hair collection (at least 6 months after disappearance of symptoms, 
patients 8, 9 and 20). Keratinocytes and PBMC were cultured either alone or together using a 
transwell culture system. To formally exclude the contamination of one cell type by the other, 
we confirmed the purity of each cell type by qPCR using primers to CD45 (PBMC marker) 
and ITGA6 (keratinocyte marker) on both PBMC and keratinocytes after a 6hr-coculture (Fig. 
S4). When keratinocytes and PBMC were each cultured alone, only PBMC showed elevated 
IL-36γ mRNA levels after exposure to the culprit drug. Interestingly, both keratinocytes and 
PBMC showed culprit drug-specific IL-36γ gene expression when cultured together (Fig. 4). 
The addition of soluble IL-36Ra did not reduce IL-36 expression, suggesting that, at the 
analyzed time point, there was no auto- or paracrine amplification and/or induction of IL-36 
gene expression by IL-36 released by PBMC or keratinocytes. Taken together, these results 
indicate that, in culprit drug-induced responses of patient-derived keratinocytes and 
monocytes, IL-36γ is the predominant form of IL-36 induced. Furthermore, in response to 
culprit drug exposure IL-36 is expressed directly by PBMC and indirectly by keratinocytes.   
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IL-36 secretion by AGEP patients’ PBMC is induced by TLR4 recognition and requires 
albumin 
Toll-like receptors (TLR) are innate immunity receptors signaling through NF-kB and leading 
to the transcription of inflammatory cytokines including IL-36γ (Aschan et al., 1990, Lian et 
al., 2012). A treatment of AGEP patients’ PBMC exposed to culprit drug with an inhibitory 
peptide to the TLR adapter protein MYD88 (Pepinh-MYD) led to a decreased IL-36γ 
secretion as compared to vehicle. Moreover, the inhibition of TLR4 signaling with a 
neutralizing antibody also resulted in a decreased IL-36γ secretion by PBMC exposed to 
culprit drug whereas a neutralizing antibody to TLR2 had no effect on IL-36γ expression (Fig. 
4b). Since MyD88 is also involved in IL-1RI/IL-1 signaling, we also treated drug-exposed 
PBMC from AGEP patients with a recombinant IL-1 receptor antagonist (IL-1Ra). IL-1Ra 
was also able to partially reduce IL-36 production in response to the culprit drug, however to 
a significant lesser extent than the TLR4-neutralizing antibody.   
Albumin is the most abundant serum protein and is known to have high ligand-binding 
capacities (Fasano et al., 2005). It has also been reported to be a major target for drugs such as 
amoxicillin and to be required for the induction of immediate hypersensitivity reactions to 
drugs (Ariza et al., 2016). To assess whether albumin was required for IL-36γ secretion by 
AGEP patients’ cells exposed to culprit drugs, cells were first exposed to culprit and control 
drugs in the absence of proteins in the culture medium (serum-free). In the latter condition, 
culprit drug-induced IL-36γ secretion was dramatically decreased (Fig. 4c). Interestingly, the 
medium supplementation with albumin restored the ability of PBMCs to secrete IL-36γ in 
response to drugs. Together, these results suggest that drug-albumin complex is sensed by 
TLR4 as danger signal in patients having experienced AGEP. 
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Selective, IL-36-induced IL-8 production by patients’ PBMC  
IL-8 has been previously reported to be produced by drug-specific T cells in AGEP patients 
(Britschgi et al., 2001) and in accordance with this, IL-8 expression was significantly 
upregulated in AGEP skin when compared to healthy skin (ratio=2.25, p=0.01; Table S2) but 
also when compared to MPR (ratio=2.24, p=0.008; Table S3) as revealed by Affymetrix gene 
expression array (Fig. 1a). We could confirm this by qPCR (Fig. 5a, left panel). 
Immunohistochemistry analyses further confirmed that IL-8 was overexpressed in AGEP as 
compared to MPR and healthy skin and that cells of the infiltrate in pustular regions of AGEP 
skin were the main source of IL-8 (Fig. 5a, right panels). As previously reported, IL-36 is an 
inducer of IL-8 (Marrakchi et al., 2011, Towne et al., 2011, Zhang et al., 2017). Consistently, 
the exposure of PBMCs from AGEP patients to their respective culprit drug resulted in IL-8 
production that was inhibited by recombinant IL-36Ra in a dose dependent manner (Fig. S5). 
Also, using the keratinocyte/PBMC co-culture model described above, we assessed whether 
IL-36 could promote IL-8 gene expression, and if so, which cell type could produce IL-8 in 
response to IL-36. IL-8 gene expression was induced by culprit drugs in PBMC cultured 
alone - confirming our ELISPOT data - whereas it was barely detectable in isolated 
keratinocyte cultures. Levels of IL-8 gene expression in patients’ PBMC were further 
increased (4.6-fold increase over control-drug exposure, p<0.05) when co-cultured with 
autologous keratinocytes and this, selectively in response to culprit drug (Fig. 5b). In contrast, 
keratinocytes co-cultured with PBMCs produced only marginal amounts of IL-8. 
Interestingly, in this autologous co-culture model, the upregulation of IL-8 gene expression in 
AGEP patients PBMC was abrogated by IL-36Ra. Altogether, these results indicate that 
PBMC are the main source of drug-induced IL-8 production, and that IL-8 production is 
dependent on PBMC- and/or keratinocyte-derived IL-36. 
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DISCUSSION 
 
T cells and neutrophils are considered to be major players in AGEP (Britschgi et al., 2001, 
Feldmeyer et al., 2016). It has been proposed that drugs causing AGEP elicit drug-specific T 
cell responses, and that these T cells secrete IL-8 (Britschgi et al., 2001). Recently, mutations 
in the IL-36RN gene have been reported in AGEP (Navarini et al., 2013), suggesting that a 
deregulation in IL-36 signaling may contribute to the physiopathology of AGEP. Our data is 
supportive of this hypothesis, showing that culprit drugs can directly induce IL-36γ secretion 
in AGEP patients’ cells in vitro. Analysis of IL-36 gene and protein expression ex vivo is also 
supportive of the above and, furthermore, reveal that macrophages and keratinocytes are the 
main producers of IL-36 in the pustular areas of AGEP skin. IL-36γ was found to be the 
predominant form of IL-36 expressed in AGEP skin biopsies. Interestingly, causative drugs 
were able to induce IL-36γ and subsequent IL-8 production in PBMC taken from patients 
months to years after AGEP resolution whereas these cytokines could not be induced by drugs 
in healthy control donors who had never experienced an adverse drug reaction. This is, to our 
knowledge, the first experimental and translational evidence that the innate immune system is 
able to mount fast pro-inflammatory response selectively to the culprit drug and exclusively 
in AGEP patients via the production of IL-36γ. Indeed, such a production by monocytes and 
keratinocytes from patients could be observed as early as 1 hr after culprit drug exposure in 
vitro. To further support a role for innate immunity in AGEP, we also provide evidence that 
TLR4 is involved in the sensing of culprit-drug/albumin complex as a danger signal inducing 
IL-36γ exclusively in PBMC from patients having experienced AGEP.  
Keratinocytes are a major source of IL-36 cytokines in cutaneous inflammation, particularly 
in psoriasis (Carrier et al., 2011). Our data suggests that keratinocytes are also an important 
source of IL-36 in the skin in AGEP. However, co-culture experiments revealed that 
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keratinocytes exposed to culprit drugs were only able to produce high amounts of IL-36γ 
when cultured in presence of autologous monocytes and culprit drug. This observation 
suggests that, when exposed to the causative drug, patients’ monocytes release a soluble 
factor that further stimulates IL-36γ production by keratinocytes. This factor remains to be 
identified but our results using IL-36Ra suggest that it is very likely not IL-36 itself at an 
early time point. Indeed, unlike what has been reported in psoriasis (Carrier et al., 2011), we 
could not observe any IL-36 induction by IL-36 itself in AGEP patients’ keratinocytes at the 
early time-point of 6 hrs after drug stimulation as evidenced by the lack of effect of IL-36Ra.  
We also observed that the use IL-1Ra led to a reduced IL-36γ production by AGEP patients’ 
PBMCs exposed to culprit drugs. A great overlap in IL-1 family gene upregulation by IL-1β 
and IL-36γ has been recently reported (Swindell et al., 2018). This overlap includes genes 
encoding IL-1β and IL-36 themselves that can be induced by either cytokine suggesting an 
IL-1β-IL-36γ amplifying loop in PBMC stimulated by culprit drugs. The extent of IL-36 γ 
inhibition by IL-1Ra was however significantly lower than the one seen with a blocking 
antibody to TLR4. The important role of IL-36 in response to certain drugs in AGEP patients 
is further supported by the inhibition of IL-8 by IL-36Ra, the latter cytokine being already 
suspected to cause neutrophil recruitment and survival in lesional skin during the course of 
AGEP (Schaerli et al., 2004). 
Like in other inflammatory diseases such as psoriasis (Nickoloff, 2006), contact 
hypersensitivity (Watanabe et al., 2007) or sunburn (Feldmeyer et al., 2007), keratinocytes 
may actively participate in the pathogenesis of AGEP by secreting IL-36, which could 
contribute to the herein observed and previously reported induction of IL-8 gene expression 
by macrophages. IL-8 may also originate from drug-specific T cells in AGEP (Britschgi et al., 
2001). However, the mechanisms leading to drug-specific T cell priming and recruitment to 
the skin in AGEP have not been elucidated to date. Unlike murine T cells, human T cells do 
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not express IL-36R (Foster et al., 2014) but, in AGEP, IL-36 may nevertheless contribute to T 
cell-mediated immune responses through its strong stimulatory effects on antigen-presenting 
cells (Vigne et al., 2011). Our findings that IL-36γ can be induced by a drug very early in 
innate immune cells do not exclude a delayed drug-specific T cell response but whether the 
induction of IL-36γ in monocytes by culprit drugs and the activation of drug-specific T cells 
are dependent events in AGEP pathogenesis or not remains to be investigated. 
Th17 cells may also be involved in AGEP as revealed by their previously reported increased 
frequencies and elevated IL-22 blood levels in AGEP patients (Kabashima et al., 2011). IL-17 
is known to increase IL-8 secretion by keratinocytes (Pennino et al., 2010) in allergic contact 
dermatitis (Albanesi et al., 1999) and in psoriasis (Chiricozzi et al., 2011). Our in vitro data 
revealed however that in response to IL-36, the major source of IL-8 was patients’ monocytes, 
consistently with the previously reported elevated expression of IL-36R and potential strong 
responsiveness to IL-36 by dermal myeloid cells (Dietrich et al., 2016). Although 
keratinocytes also express high levels of IL-36R (Dietrich et al., 2016), IL-8 production by 
keratinocytes was marginal as confirmed by qPCR in co-culture experiments and 
immunohistochemistry where IL-8 was only detected in the peri-pustular immune infiltrate 
(Fig. 5). 
Although mutations in the IL-36RN gene have been identified in AGEP patients, no other 
marker(s) of genetic predisposition have been formally identified for AGEP to date. 
Noteworthy, our data shows that a deregulation of the IL-36-IL-8 axis can occur 
independently of IL-36RN mutations in AGEP, suggesting that other factors influencing the 
susceptibility to an IL-36-mediated proinflammatory response to culprit drugs are at play in 
AGEP patients.  
Overall, we provide evidence that IL-36 is involved in AGEP pathogenesis, and identify 
monocytes and keratinocytes as potential key producers of IL-36 in this ADR. We also 
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identify TLR4 as an essential pattern recognition receptor involved in the sensing of 
drug/albumin complex as a danger signal in AGEP patients. Further supportive of our 
findings is the very rapid onset of the disease after the first intake of a drug, suggesting an 
early response mediated by the innate immune system. However, the mechanisms or factors 
conferring such a responsiveness to certain drugs to monocytes and keratinocytes in AGEP 
patients remain to be identified and require extensive investigations. Given that 
monocytes/PBMC of all AGEP patients tested have an enhanced propensity to produce IL-36γ 
upon culprit drug exposure, the identification of predictive markers that would help identify 
patients prone to pathological IL-36γ production upon exposure to certain medications may be 
achievable.  
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MATERIALS AND METHODS 
 
Patients and biological material collection 
The characteristics of all studied AGEP patients from the Dermatology Department of the 
University Hospital of Zürich are presented in Tables 1 and Table S4. All human samples 
were collected after informed written patient consent with approval of Local Ethics 
Committees and according to the Declaration of Helsinki Principles. 4-6mm punch skin 
biopsies were taken from lesional skin of patients in the acute phase of the ADR. Healthy skin 
samples were obtained from the Department of Plastic Surgery, University Hospital of Zürich. 
For paraffinization, skin samples were fixed in formalin 4% overnight. For RNA isolation, 
samples were snap-frozen in liquid nitrogen and stored at -80°C. Peripheral blood from 
patients was taken both in the acute phase of the disease and under healthy conditions (at least 
6 months after the ADR). Healthy controls were obtained from the Blood Donation Center 
(Schlieren, Switzerland). Peripheral blood mononuclear cells (PBMC) were isolated using a 
density gradient (Ficoll-Paque, Pharmacia, Glattbrugg, Switzerland).  
 
Monocyte and T cell purification 
Where indicated, CD14+ monocytes were sorted from PBMC by positive selection using 
magnetic beads (Miltenyi Biotech, Bergisch Gladbach, Germany). CD3+ cells were sorted 
from the CD14- fraction by negative selection using a Pan T Cell Isolation Kit (Miltenyi 
Biotech) according to the manufacturer’s instructions. Purity was assessed by flow cytometry 
(Facscanto A, Becton-Dickinson) using mouse anti-human CD45-PeCy7 (Biolegend, San 
Diego, CA), mouse anti-human CD3-APC (Biolegend) and mouse anti-human CD14-FITC 
(Becton-Dickinson, Franklin Lakes, NJ). 
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Primary keratinocyte culture 
Hair follicles were collected from patients at least 6 months after resolution of the ADR. Hair 
follicle extremities containing outer root sheath were cut, washed in complete keratinocyte 
medium (Strittmatter et al., 2016) and incubated for 3 minutes in 1mg/ml Dispase II, followed 
by three washing steps in medium. The hair was then plated on J2 feeder cells in complete 
medium and cultured until small colonies of keratinocytes become visible. Cells were splitted 
at 80% confluence and passaged three times before being used for experiments.   
 
Co-culture experiments 
PBMC and keratinocytes used in these experiments were collected at least 6 months after 
resolution of the ADR. 70.000 AGEP hair follicle keratinocytes were plated on a 12mm 
transwell plate with 0.4µm pore polycarbonate membrane inserts (Corning, NY, USA) 
overnight to allow them to adhere. The following day, keratinocyte medium was replaced by 
Gibco Opti-MEM medium (Thermo Scientific) and 1x106 PBMC were added inside the 
inserts, followed by addition of culprit drug (Amoxicillin 1mg/ml; Letrozole 100nM; 
Vancomycin 500µg/ml) or control drug (Metamizole 100µg/ml; Carbamazepine 10µg/ml; 
Amoxicillin, 1mg/ml) or vehicle (RPMI medium containing 10% FBS)  in both compartments 
at the same concentration +/- IL-36 inhibition by an IL-36RA (R&D Systems, 1µg/ml). After 
6 hours, cells were harvested and RNA was isolated for quantitative RT-PCR analysis. 
 
Toll-like receptor and IL-1 inhibition 
PBMC were isolated from AGEP patients and cultured in ELISPOT plates. Cells were 
stimulated with the culprit drug in the presence or absence of the MyD88 inhibitory peptide 
Pepinh-MYD (Invivogen, San Diego, CA, 25mM), anti-TLR2 antibody (R&D Systems, 
Clone # 383936, 5µg/ml), anti-TLR4 antibody (R&D Systems, Polyclonal Goat IgG, 5µg/ml), 
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control IgG antibody (5µg/ml) and IL-1RA (Anakinra, Biovitrum AB, 1µg/ml). Untreated 
cells and irrelevant control drug served as controls. 
 
Statistical analyses 
Differences between groups were assessed using one-way Anova followed by Turkey’s post-
test. Differences were considered significant when: *p≤0.05, ** p≤0.01 and *** p≤0.001 and 
**** p≤0.0001. 
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Table 1. AGEP patients – Patch and Prick tests, LTT, culprit drugs and presence of IL36RN 
mutations 
 
 
 
Nr. Patch test Prick LTT Drug IL36RN 
1 N.A. negative negative Amoxicillin n.d. 
2 N.A. N.A. N.A. Terbinafin n.d. 
3 negative negative negative Metformin No mutation 
4 negative negative N.A. unknown  No mutation 
5 positiv positive negative unknown n.d. 
6 negative negative negative Lonsoprazol / Clarithromycin 
n.d. 
7 N.A. N.A. N.A. unknown n.d. 
8 N.A. N.A. positive Amoxicillin No mutation 
9 N.A. N.A. positive Letrozole n.d. 
10 positive positive positive Amoxicillin No mutation 
11 N.A. N.A. N.A. Amoxicillin n.d. 
12 N.A. N.A. N.A. Floxapen n.d. 
13 negative negative N.A. Ceftriaxon n.d. 
14 N.A. N.A. N.A. 
Ciprofloxacin / 
Metamizol / 
Paracetamol  
n.d. 
15 N.A. N.A. N.A. Amoxicillin n.d. 
16 positive positive negative Novalgin n.d. 
17 negative negative N.A. Ibuprofen / Pure Life Cleanse 
No mutation 
18 N.A. N.A. N.A. Terbinafin n.d. 
19 positive positive positive unknown n.d. 
20 N.A. N.A. N.A. Vancomycin n.d. 
21 N.A. N.A. positive Fluconazole n.d. 
22 N.A. N.A. N.A. Unknown n.d. 
23 N.A. N.A. N.A. unknown n.d. 
24 N.A. N.A. N.A. Amoxicillin n.d. 
25 N.A. N.A. N.A. Amoxicillin n.d. 
26 N.A. N.A. positive Acetazolamide n.d. 
27 N.A. N.A. N.A. Cotrimoxazole n.d. 
28 Positive Positive negative 
Cotrimoxazole / 
Codein / 
Paracetamol 
n.d. 
29 N.A. N.A. Positive Lisinopril n.d. 
 
n.d.: not determined; in bold: cells from these patients have been used in experiments shown 
in figures 3, 4 and 5. 
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FIGURE LEGENDS 
 
Figure 1. IL-36α and IL-36γ are overexpressed in pustular regions of AGEP lesional skin.  
(a) Gene expression hierarchical clustering in lesional skin biopsies from patients suffering 
from AGEP (n=8) and MPR (n=6) analyzed using Affymetrix Human Exon 1.0 ST chips and 
(b) quantitative RT-PCR analysis of IL-36α, IL-36β, IL-36γ, IL-36R, IL-36RN in skin 
biopsies from AGEP patients (n=16), MPR (n=16) and normal skin (NS; n=5). (c) 
Immunohistochemical analysis of lesional skin biopsies revealed that IL-36α and IL-36γ are 
overexpressed at the site of pustules in AGEP and PP controls. Representative pictures of 18 
AGEP, 10 PP and 18 MPR cases are shown (scale bar in the large panels=500µm; scale bar in 
the small panels=100µm). Neither IL-36α, nor IL-36γ were detectable in normal skin (NS) 
from healthy donors (Fig. S1a). Bottom panels show the semi-quantitative evaluation of IL-
36α and IL-36γ labeling by immunohistochemistry in the pustular epidermis, non-pustular 
epidermis, and dermis (Fig. S1b) of lesional skin biopsies from patients with AGEP (n=18), 
PP (n=10), MPR (n=18) and normal skin (NS) from healthy donors (n=5). Expression levels 
were qualified as very strong (++++), strong (+++), moderate (++), weak (+) or absent (0). 
*p<0.05; **p<0.01; *** p<0.001; **** p<0.0001. 
 
Figure 2. IL-36γ is expressed by keratinocytes and immune cells in AGEP skin. 
Pustule-containing sections of AGEP skin samples were co-labeled with antibodies to CD68 
(green), CD3 (green) and IL-36α (red) (a) or IL-36γ (red) (scale bar in the large 
panels=500µm; scale bar in the small panels=20µm) (b). The percentage of epidermal cells 
(keratinocytes), CD68 and CD3-labeled cells among the IL-36α or IL-36γ-labeled cells was 
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determined (c). Cell nuclei appear in blue (DAPI). The mean±SD of 12 examined patients is 
shown (patients 8-10 and 20-28). *p<0.05; *** p<0.001. 
Figure 3. PBMC and monocytes taken from AGEP patients more than 6 months after the 
ADR selectively secrete IL-36γ in response to culprit drug exposure. 
(a) PBMC from AGEP or MPR patients as well as healthy donors were cultured in IL-
36γ ELISPOT plates for 8 hrs in presence of the culprit drug having caused AGEP or MPR, 
respectively (left panel) or a control drug (right panel). The number of spots was counted 1, 2, 
4, 6 and 8 hrs after drug exposure. The means±SD of 3 different AGEP patients (no. 8, 10 and 
21), 3 MPR patients and 3 healthy blood donors are shown. (b) CD14+ monocytes and CD3+ 
T cells were isolated from AGEP blood with a purity of >96% (right panel) and were cultured 
in IL-36γ ELISPOT plates (left panel) in presence of the culprit drug or a control drug and 
compared to total PBMC. The number of spots was counted 8 hrs after drug exposure (lower 
panel). The mean±SD of 3 different patients (patient no. 8, 9 and 10) is shown. **p<0.01; 
***p<0.001. 
 
Figure 4. IL-36γ is specifically induced by culprit drugs in PBMC and keratinocytes and is 
dependent on TLR4 and albumin.. 
(a) Autologous PBMC and keratinocytes (KC) from patients having experienced AGEP but in 
remission at the time of blood and hair collection were cultured either alone or together in a 
transwell system allowing for soluble factor-mediated interactions. Patients’ cells were 
exposed to the culprit drug (Amoxicillin 1mg/ml, patient 8; Letrozole 100nM, patient 9; 
Vancomycin 500µg/ml, patient 20) or a control drug (Metamizole 100µg/ml, patient 8; 
Carbamazepine 10µg/ml, patient 9; Amoxicillin 1mg/ml, patient 20) in presence or absence of 
IL-36RA (1µg/ml). After 6 hrs of culture, RNA was extracted from KC (left panels) and 
PBMC (right panels) to measure IL-36γ mRNA levels. Relative IL-36γ expression in KC and 
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PBMC cultured either alone or in co-culture as indicated and exposed to the culprit drug or a 
control drug in presence or absence of IL-36Ra are shown for each tested patient. Means±SD 
of 3 replicates are shown. (b) PBMC from AGEP patients were pretreated with vehicle, 
MyD88 inhibitory peptide, neutralizing antibodies to TLR2 and TLR4 or recombinant IL-1 
receptor antagonist (IL-1RA) and exposed to culprit drug for 6 hours. An ELISPOT assay was 
performed and the number of IL-36γ+ spots were counted using an ELISPOT reader. 
Untreated cells or cells exposed to an irrelevant control drug were used as basal IL-36γ 
secretion controls. Mean±SD of the 5 tested patients is shown. ***p<0.001. (c) PBMC from 
AGEP patients were exposed to culprit drug for 6 hours in medium containing 10% FBS or in 
serum free medium or in serum free medium supplemented with 2.5 mg/ml human serum 
albumin (HSA) as indicated. An ELISPOT assay was performed and the numbers of IL-36γ+ 
spots were counted using an ELISPOT reader. Untreated cells were used as basal IL-36γ 
secretion controls. Mean±SD of the 5 tested patients is shown. *p<0.05; ***p<0.001. 
Representative IL-36γ ELISPOT pictures are shown below the graph. 
 
Figure 5. IL-8 is expressed in lesional skin biopsies from patients suffering from AGEP and is 
induced in patients’ PBMC by IL-36. 
(a) Quantitative RT-PCR analysis of IL-8 in lesional skin biopsies of patients suffering from 
AGEP (n=16), MPR (n=16) and normal skin (NS; n=5). Immunohistochemical analysis of 
lesional skin biopsies revealed that IL-8 is expressed at the site of pustules in AGEP in dermal 
immune cells but not by keratinocytes (scale bar in the left panels=300µm; scale bar in the 
right panels=50µm). Representative picture of 18 AGEP cases is shown (upper panels). IL-8 
was not detectable in normal skin from healthy donors (lower panels). (b) Quantitative PCR 
analysis of IL-8 gene expression in PBMC (upper panels) and KC (lower panels) from patient 
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8 (Amoxicillin 1mg/ml), patient 9 (Letrozole 100nM) and patient 20 (Vancomycin 500µg/ml), 
cultured either alone or in co-culture as indicated and exposed to the drug having cause AGEP 
or a control drug in the presence or absence of IL-36Ra. Gene expression reported as 2-∆CT, 
which represents the target gene expression relative to the reference gene (RPL27). Mean±SD 
of the 3 tested patients is shown. The figure illustrates a representative experiment that was 
repeated 3 times for each patient. *p<0.05; **p<0.01; ***p<0.001. 
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